Sort
10,766 grants matching “checkpoint inhibitor”
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
$466,517Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
$466,514Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Genetic screens for IR resistance
$466,400Dana-Farber Cancer Institute · U19 · FY2005 · AI
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
$466,346Ralph P Mason · Ut Southwestern Medical Center · R01 · FY2022 · CA
Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients
$466,152Scott H Kaufmann · Mayo Clinic Rochester · R01 · FY2025 · CA
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
$465,921J. Silvio Gutkind · University Of California, San Diego · R01 · FY2020 · DE
Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma
$465,743Abraham Ari Hakimi · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Investigating multifactorial beta-catenin activation in hepatocellular cancers
$465,707Xin Chen · University Of Hawaii At Manoa · R01 · FY2024 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$465,623Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2024 · CA
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$465,558Triparna Sen · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
$465,473J. Silvio Gutkind · University Of California, San Diego · R01 · FY2019 · DE
S100A4 mediated immune suppression in GBM
$465,405Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2021 · NS
The Mre11 complex: linking recombination to checkpoints
$465,376Sloan-Kettering Institute For Cancer Res · R01 · FY2004 · GM
Defining and Targeting Homologous Recombination Deficiency in Breast Cancer
$465,347Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2021 · CA
Defining and Targeting Homologous Recombination Deficiency in Breast Cancer
$465,347Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA
CRAF-mediated vascular resistance to cancer therapies
$465,256David A Cheresh · University Of California, San Diego · R01 · FY2016 · CA
CRAF-mediated vascular resistance to cancer therapies
$465,256David A Cheresh · University Of California, San Diego · R01 · FY2015 · CA
CRAF-mediated vascular resistance to cancer therapies
$465,256David A Cheresh · University Of California, San Diego · R01 · FY2017 · CA
Metabolic basis of ARID1A-mutated ovarian cancer
$465,225Rugang Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
$465,002Wei R. Chen · University Of Oklahoma · R01 · FY2024 · CA
Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity
$464,718Kimmie Ng · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Targeting Autophagy in Hereditary Breast Cancer
$464,713Bing Xia · Rbhs -Cancer Institute Of New Jersey · R01 · FY2019 · CA
Cyclin-dependent kinase control of cell-division and transcription cycles
$464,704Robert P Fisher · Icahn School Of Medicine At Mount Sinai · R35 · FY2021 · GM
Cyclin-dependent kinase control of cell-division and transcription cycles
$464,704Robert P Fisher · Icahn School Of Medicine At Mount Sinai · R35 · FY2018 · GM
Cyclin-dependent kinase control of cell-division and transcription cycles
$464,704Robert P Fisher · Icahn School Of Medicine At Mount Sinai · R35 · FY2019 · GM